Bristol Myers BMY has a strong oncology portfolio, together with the blockbuster immune-oncology medication, Opdivo, Opdivo Qvantig and Yervoy, amongst others.
Opdivo is a key drug in BMY’s progress portfolio that’s accepted for a number of oncology indications. The drug, accepted for quite a few oncology indications, is among the high income mills for BMY.
Constant label enlargement of the drug has enabled it to take care of momentum. Opdivo gross sales had been roughly $2.5 billion within the third quarter, up 7%, pushed primarily by continued demand. U.S. gross sales are being pushed by a powerful launch in MSI-high colorectal most cancers and continued progress in first-line non-small cell lung most cancers, whereas worldwide gross sales are supported by label expansions of the drug.
The approval of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use has bolstered Opdivo’s franchise. The preliminary uptake has been sturdy. Gross sales totaled $67 million within the third quarter, fueled by continued use throughout all indicated tumor varieties in addition to the everlasting J-Code acquired within the quarter.
The corporate now expects international Opdivo gross sales, along with Qvantig, to extend within the excessive single digit to low double-digit vary in 2025 (earlier steerage: mid to excessive single-digit vary in 2025), pushed by sturdy efficiency 12 months so far.
We observe that BMY is presently banking on the label enlargement of accepted medication and approval of latest medication to stabilize its income base, as its legacy medication (Revlimid, Pomalyst, Sprycel and Abraxane) face generic competitors.
Competitors for BMY’s Oncology Medicine
Whereas the label enlargement of Opdivo is optimistic, the immuno-oncology area is dominated by pharma large Merck’s MRK blockbuster drug Keytruda (pembrolizumab), together with Roche’s RHHBY Tecentriq.
Keytruda is accepted for a number of sorts of most cancers and alone accounts for greater than 50% of MRK’s pharmaceutical gross sales. Merck is presently engaged on completely different methods to drive long-term progress of Keytruda.
Roche’s immuno-oncology Tecentriq can also be accepted for numerous oncology indications — early-stage (adjuvant) NSCLC, small cell lung most cancers, hepatocellular carcinoma and breast most cancers, amongst others. Along with intravenous infusion, Roche has additionally obtained approval for Tecentriq as a subcutaneous injection.
BMY’s Value Efficiency, Valuation and Estimates
Shares of Bristol Myers have misplaced 12.9% 12 months so far towards the trade’s progress of 19.5%.
Picture Supply: Zacks Funding Analysis
From a valuation standpoint, BMY is buying and selling at a reduction to the large-cap pharma trade. Going by the value/earnings ratio, BMY’s shares presently commerce at 8.17x ahead earnings, decrease than its imply of 8.40x and the large-cap pharma trade’s 17.47X.
Picture Supply: Zacks Funding Analysis
The Zacks Consensus Estimate for 2025 earnings per share has moved north prior to now 60 days, whereas that for 2026 EPS has moved south.
Picture Supply: Zacks Funding Analysis
BMY presently carries a Zacks Rank #3 (Maintain). You’ll be able to see the whole listing of right this moment’s Zacks #1 Rank (Robust Purchase) shares right here.
Quantum Computing Shares Set To Soar
Synthetic intelligence has already reshaped the funding panorama, and its convergence with quantum computing might result in essentially the most important wealth-building alternatives of our time.
In the present day, you might have an opportunity to place your portfolio on the forefront of this technological revolution. In our pressing particular report, Past AI: The Quantum Leap in Computing Energy, you may uncover the little-known shares we imagine will win the quantum computing race and ship huge beneficial properties to early traders.
Roche Holding AG (RHHBY) : Free Inventory Evaluation Report
Bristol Myers Squibb Firm (BMY) : Free Inventory Evaluation Report
Merck & Co., Inc. (MRK) : Free Inventory Evaluation Report
This text initially revealed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
